Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Abstract	Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.
Authors	Jatin Shah, Sharon Shacham, Michael Kauffman, Patrick Daniele, Dimitrios Tomaras, Gabriel Tremblay, Rene-Olivier Casasnovas, Marie Maerevoet, Josee Zijlstra, George Follows, Joost S P Vermaat, Nagesh Kalakonda, Andre Henri Goy, Sylvain Choquet, Eric Van Den Neste, Brian T Hill, Catherine Thieblemont, Federica Cavallo, Fátima de la Cruz, John Kuruvilla, Nada Hamad, Reda Bouabdallah, Ulrich Jäger, Paolo Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan Manuel Sancho, Michael Schuster, Miklós Egyed, Fritz Offner, Theodoros P Vasilakopoulos, Priyanka Samal, Agnes Nagy, Matthew Ku, Miguel Ángel Canales Albendea
Journal	Future oncology (London, England) (Future Oncol) Vol. 17 Issue 11 Pg. 1295-1310 (Apr 2021) ISSN: 1744-8301 [Electronic] England
PMID	33528286 (Publication Type: Clinical Trial, Phase II, Journal Article)
Chemical References	Hydrazines Triazoles selinexor
Topics	Adult Aged Aged, 80 and over Drug Resistance, Neoplasm Female Humans Hydrazines (therapeutic use) Lymphoma, Large B-Cell, Diffuse (drug therapy, pathology) Male Middle Aged Patient Reported Outcome Measures Quality of Life Recurrence Triazoles (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!